論文 - 山上　亘

LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium

Imaeda K, Tamura T, Nagai S, Sugihara E, Yamasaki J, Otsuki Y, Nakamura K, Takeda T, Nakamura K, Nogami Y, Tsuji K, Chiyoda T, Kisu I, Kobayashi Y, Banno K, Yamaguchi R, Sakurada K, Saya H, Aoki D, Ahmed AA, Nagano O, Masuda K, Yamagami W

iScience 28 （ 6 ） 112654 - 112654 2025年06月

研究論文（学術雑誌）, 共著

Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification

Yoshimura T, Nakamura K, Chiyoda T, Takamatsu R, Kawano R, Aimono E, Kawaida M, Sakai K, Masugi Y, Nishihara H, Yamagami W

BJC Rep 3 （ 1 ） 37 - 37 2025年05月

研究論文（学術雑誌）, 共著

CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation

Nagase Y, Kodama M, Aimono E, Nakamura K, Takamatsu R, Abe K, Yoshimura T, Chiyoda T, Yamagami W, Nishihara H

Cancer Sci 116 （ 5 ） 1193 - 1202 2025年05月

研究論文（学術雑誌）, 共著

Prognostic impact of peritoneal cytology on treating endometrial cancer using data from the Japan Society of Obstetrics and Gynecology cancer registry

Sakai K, Yamagami W, Takahashi F, Tokunaga H, Yamamoto E, Yokoyama Y, Yoshino K, Kawana K, Nagase S

J Gynecol Oncol 36 （ 3 ） e41 - e41  2025年05月

研究論文（学術雑誌）, 共著

mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer

Tamura T, Nagai S, Masuda K, Imaeda K, Sugihara E, Yamasaki J, Kawaida M, Otsuki Y, Suina K, Nobusue H, Akahane T, Chiyoda T, Kisu I, Kobayashi Y, Banno K, Sakurada K, Okita H, Yamaguchi R, Ahmed AA, Yamagami W, Saya H, Aoki D, Nagano O

Cancer Lett 616   217565 - 217565 2025年04月

研究論文（学術雑誌）, 単著

難治性のほてり・発汗に対して補腎剤が著効した3症例

横田めぐみ，椎名美季，大野あゆみ，谷本慧子，堀場裕子，山上 亘

産婦人科漢方研究のあゆみ 40   58 - 62 2025年04月

研究論文（学術雑誌）, 共著

めまいを訴える更年期女性への漢方処方と効果

椎名美季，横田めぐみ，大野あゆみ，谷本慧子，堀場裕子，山上 亘

産婦人科漢方研究のあゆみ 40   26 - 30 2025年04月

研究論文（学術雑誌）, 共著

横紋筋融解症を発症し早産に至った筋強直性ジストロフィー合併妊娠の1例

山田 郁，大谷利光，緒方泰彦，石川直嗣，梶川かおる，秋田啓介，玉井順子，田中雄也，春日義史，池ノ上 学，山上 亘，田中 守

東京産科婦人科学会会誌 74 （ 2 ） 367 - 370 2025年04月

共著, 査読有り

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Marth C., Moore R.G., Bidziński M., Pignata S., Ayhan A., Rubio M.J., Beiner M., Hall M., Vulsteke C., Braicu E.I., Sonoda K., Wu X., Frentzas S., Mattar A., Lheureux S., Chen X., Hasegawa K., Magallanes-Maciel M., Choi C.H., Shalkova M., Kaen D., Wang P.H., Berger R., Okpara C.E., McKenzie J., Yao L., Orlowski R., Khemka V., Gilbert L., Makker V., Gomez Abuin G., Zamora L.B., Alfie M.S., Casarini I.A., Harrison M., Ananda S., Shannon C.M., Friedlander M., Meniawy T., Gao B., Baron-Hay S., Diakos C., Polterauer S., Petru E., De Bock M., Baurain J.F., Van Gorp T., Altintas S., Lima J.P.D.S.N., De Freitas Junior R., Santana R.O., De Melo A.C., Franke F.A., Zibetti Dal Molin G., Damian F.B., Guedes J.D.C., Ellard S., Tinker A., Samouëlian V., Fortin S., Bessette P., Kolinsky M., Kumar Tyagi N., Ethier J.L., MacKay H., Lim C., Pan L., An R., Zheng H., Wu Y., Zhu J., Yao S., Jia X., Huang Y., Lv W., Zhang Y., Zhou Q., Ma C., Chekerov R., Mach P., Witteler R., Marmè F., Cadoo K., Korach J., Levy T., Amnon A., Scollo P., Naglieri E., Zamagni C., Salutari V., Usami T., Nakamura K., Matsumoto K., Yamagami W., Kobayashi Y., Takano M., Kato H., Kikuchi A., Katsumata N.

Journal of Clinical Oncology 43 （ 9 ） 1083 - 1100 2025年03月

研究論文（学術雑誌）,  ISSN  0732183X

　概要を見る

PURPOSELenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) in the phase III Study 309/KEYNOTE-775. We report results from the phase III, randomized, open-label European Network of Gynaecological Oncological Trial-en9/LEAP-001 study (ClinicalTrials.gov identifier: NCT03884101) that evaluated len + pembro versus chemotherapy in first-line aEC.METHODSPatients with stage III to IV or recurrent, radiographically apparent EC and no previous chemotherapy or disease progression ≥6 months after neo/adjuvant platinum-based chemotherapy were randomly assigned 1:1 to lenvatinib 20 mg once daily plus pembrolizumab 200 mg once every 3 weeks or paclitaxel 175 mg/m² plus carboplatin AUC 6 mg/mL/min once every 3 weeks. Primary end points were PFS and OS, evaluated in the mismatch repair-proficient (pMMR) and all-comers populations. Noninferiority was assessed for OS at final analysis (FA) for len + pembro versus chemotherapy (multiplicity-adjusted, one-sided nominal alpha,.0159; null hypothesis-tested hazard ratio [HR], 1.1).RESULTSEight hundred forty-two patients were randomly assigned (len + pembro, n = 420 [pMMR population, n = 320]; chemotherapy, n = 422 [pMMR population, n = 322]). At FA (data cutoff, October 2, 2023), median PFS (95% CI) in the pMMR population was 9.6 (8.2 to 11.9) versus 10.2 (8.4 to 10.5) months with len + pembro versus chemotherapy (hazard ratio [HR], 0.99 [95% CI, 0.82 to 1.21]) and among all-comers was 12.5 (10.3 to 15.1) versus 10.2 (8.4 to 10.4) months (HR, 0.91 [95% CI, 0.76 to 1.09]; descriptive analyses). Median OS (95% CI) in the pMMR population was 30.9 (25.4 to 37.7) versus 29.4 (26.2 to 35.4) months with len + pembro versus chemotherapy (HR, 1.02 [95% CI, 0.83 to 1.26]; noninferiority P =.246, not statistically significant per multiplicity control strategy) and among all-comers was 37.7 (32.2 to 43.6) versus 32.1 (27.2 to 35.7) months (HR, 0.93 [95% CI, 0.77 to 1.12]). Grade ≥3 treatment-related adverse events occurred in 331/420 (79%) versus 274/411 (67%) treated patients.CONCLUSIONFirst-line len + pembro did not meet prespecified statistical criteria for PFS or OS versus chemotherapy in pMMR aEC.

• Access to Document (DOI)

Immunotherapy for endometrial cancer

Wada M, Yamagami W

Int J Clin Oncol 30 （ 3 ） 449 - 456 2025年03月

研究論文（学術雑誌）

子宮内膜異型増殖症に対する鏡視下子宮全摘出術前における、子宮内膜全面掻爬術の有用性に関する検討

坂巻智美，吉村拓馬，落合大輔，地阪光代，平田 桃，高橋美央，坂井健良，和田美智子，千代田達幸，山上 亘，田中 守

東京産科婦人科学会会誌 74 （ 1 ） 8 - 12 2025年01月

研究論文（学術雑誌）, 共著, 査読有り

Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series

Adachi T., Matsui T., Okata-Karigane U., Takahashi C., Tahara U., Hyodo M., Miyagawa A., Kobayashi K., Nakamura Y., Funakoshi T., Nishio H., Yamagami W., Takahashi H.

Journal of Dermatology 52 （ 1 ） 132 - 137 2025年01月

研究論文（学術雑誌）, 共著,  ISSN  03852407

　概要を見る

Immune checkpoint inhibitors (ICIs), such as pembrolizumab (PEM), are widely recognized for their antitumor efficacy, but they can also lead to various cutaneous adverse events (CAEs). While most CAEs can be managed with topical corticosteroids, severe cases may necessitate halting immunotherapy. The incidence of severe CAEs is notably higher in combination therapies involving ICIs than in monotherapies, emphasizing the need for stringent, long-term management strategies. This includes potential modifications or discontinuations of the combination therapy. PEM, when added to the conventional paclitaxel + cisplatin (or carboplatin) ± bevacizumab regimen, has shown significant improvements in overall and progression-free survival for patients with Stage IVB metastatic or locally uncontrolled recurrent cervical cancer. This case series retrospectively examined the incidence and management of CAEs in 19 female patients treated with this combination therapy between October 2022 and May 2023. Four patients exhibiting CTCAE grade 3 were identified. The four cases of severe CAEs involved erythema multiforme after the initial course of PEM combination chemotherapy. Notably, three patients experienced immediate hypersensitivity reactions, including anaphylaxis, during subsequent treatments. This observation underscores the necessity for rigorous dermatological monitoring of patients undergoing PEM combination chemotherapy. Such vigilance is crucial for early detection of adverse reactions and timely adjustment of treatment regimens, thereby enhancing patient safety.

• Access to Document (DOI)

Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis

Konno Y, Mayama M, Takehara K, Yokoyama Y, Suzuki J, Susumu N, Harano K, Nakagawa S, Nakanishi T, Yamagami W, Yoshihara K, Nomura H, Okamoto A, Aoki D, Watari H

J Gynecol Oncol 36 （ 1 ） e3 - e3 2025年01月

研究論文（学術雑誌）, 共著

Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis

Takahashi M, Nakamura K, Chiyoda T, Okada C, Nohara S, Takamatsu R, Yanazume S, Kobayashi H, Nishihara H, Yamagami W

Cancer Med 14 （ 2 ） e70601 - e70601 2025年01月

研究論文（学術雑誌）, 共著

Safe Implementation of Robotic Surgery for Gynecologic Diseases at a Tertiary Center: Retrospective Analysis of 149 Cases and Review of the Literature

Yoshimura T, Nishio H, Sakai K, Nogami Y, Hayashi S, Yamagami W

Gynecol Minim Invasive Ther 14 （ 1 ） 33 - 39 2024年12月

研究論文（学術雑誌）

The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.

Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T

Cancer discovery 14 （ 11 ） 2243 - 2261 2024年11月

ISSN  2159-8274

• Access to Document (DOI)

術中迅速病理診断で類内膜癌G1/G2,筋層浸潤1/2未満の子宮体癌に対して骨盤リンパ節郭清は必要か?

吉村拓馬，坂井健良，落合大輔，坂巻智美，地阪光代，高橋美央，吉浜智子，千代田達幸，田中 守，山上 亘

関東連合産科婦人科学会誌 61 （ 4 ） 479 - 484 2024年11月

研究論文（学術雑誌）, 共著

A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese. Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)

Sakai K, Yamagami W, Sato Y, Susumu N, Yokoyama Y, Takehara K, Mandai M, Okamoto A

J Gynecol Oncol 35 （ 6 ） e106 - e106 2024年11月

研究論文（学術雑誌）, 共著

子宮体癌における術後補助化学中に壊死性筋膜炎が疑われた1例

真鍋悠歌，横田めぐみ，高畑海音子，和田美智子，山上 亘，田中 守

東京産科婦人科学会会誌 73 （ 4 ） 811 - 817 2024年10月

研究論文（学術雑誌）, 共著, 査読有り

子宮頸管妊娠に対しメトトレキサート（MTX）と子宮動脈塞栓症（UAE）を併用し保存的治療を行った2例

白石 慧，上條慎太郎，佐久間萌子，大岡令奈，松沢優一，内田志穂，祝井麻希，内田明花，山田満稔，山上 亘，田中 守

東京産科婦人科学会会誌 73 （ 4 ） 848 - 853 2024年10月

研究論文（学術雑誌）, 共著, 査読有り